S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma
S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma
复制标题
S100P作为肝细胞癌微血管侵犯和门静脉癌栓的新型生物标志物
DOI：
10.1007/s12072-020-10130-1
复制
发表时间：
2021-01-25
影响因子：
6.6
通讯作者：
Li, Le-Qun
中科院分区：
文献类型：
--
作者：
Qi, Lu-Nan;Ma, Liang;Li, Le-Qun
门静脉癌栓（PVTT）和微血管浸润（MVI）是肝细胞癌（HCC）肝内血管转移的两种类型，与预后不良密切相关。然而，潜在的生物标志物的PVTT和MVI是unclear.MethodsWe确定了PVTT/MVI相关基因S100 P的cDNA微阵列分析，并评估血清S100 P测量的潜在价值，在肝癌的鉴别诊断和预测的MVI状态与大型回顾性和前瞻性队列study.ResultsThe mRNA和蛋白质的S100 P的增加，肝癌与PVTT或MVI。肿瘤中S100 P免疫染色高与无瘤生存率低相关。血清S100 P值可区分HCC患者和良性肝肿瘤患者，并且在回顾性和前瞻性队列中均显示MVI状态的预测潜力。结论血清S100 P可作为HCC的一种新的鉴别诊断指标，并可作为HCC患者术前MVI状态的预测指标。S100 P在肝癌中的过度表达与PVTT和MVI的形成高度相关，这可能使S100 P成为肝癌转移的潜在治疗靶点。
BackgroundPortal vein tumor thrombus (PVTT) and microvascular invasion (MVI) are types of intrahepatic vascular metastasis of hepatocellular carcinoma (HCC) and are highly correlated with poor prognosis. However, the underlying biomarkers of PVTT and MVI are unclear.MethodsWe identified a PVTT/MVI-associated gene S100P by cDNA microarray analysis, and assess the potential value of serum S100P measurement in the differential diagnosis of HCC and prediction of MVI status with large retrospective and perspective cohort studies.ResultsThe mRNA and protein of S100P was increased in HCCs with PVTT or MVI. High S100P immunostaining in tumors was correlated with inferior tumor-free survival. Serum S100P values discriminated patients with HCCs from those with benign liver tumors, and it showed predictive potential of MVI status in both retrospective and perspective cohorts. S100P may regulate HCC tumorigenicity and invasive ability; S100P also was associated with up-regulation of CD44, which may mediate HCC cell adhesion to form PVTT/MVI.ConclusionsSerum S100P may be a novel differential diagnostic marker for HCC and a potential predictor of MVI status pre-surgery for HCC patients. S100P overexpression in HCC is highly correlated with the formation of PVTT and MVI, which may make S100P as a potential therapeutic target for HCC metastasis.Graphic abstract